about
Synthesis and duplex-forming ability of oligonucleotides containing 4'-carboxythymidine analogs.Design and evaluation of locked nucleic acid-based splice-switching oligonucleotides in vitro.Evaluation of multiple-turnover capability of locked nucleic acid antisense oligonucleotides in cell-free RNase H-mediated antisense reaction and in mice.Small-molecule approaches toward the targeting of oncogenic miRNAs: roadmap for the discovery of RNA modulators.Post-SELEX optimization of aptamers.Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic MiceCa2+ enrichment in culture medium potentiates effect of oligonucleotidesSuperior Silencing by 2',4'-BNA(NC)-Based Short Antisense Oligonucleotides Compared to 2',4'-BNA/LNA-Based Apolipoprotein B Antisense InhibitorsThe small molecule Retro-1 enhances the pharmacological actions of antisense and splice switching oligonucleotides.Development of Antisense Drugs for Dyslipidemia.Phosphorothioate nucleotides and oligonucleotides - recent progress in synthesis and application.Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides.Oligonucleotide conjugates for therapeutic applications.In vitro selection of BNA (LNA) aptamers.New developments in exon skipping and splice modulation therapies for neuromuscular diseases.Synthesis and Excellent Duplex Stability of Oligonucleotides Containing 2'-Amino-LNA Functionalized with Galactose Units.Synthesis and properties of novel 2'-C,4'-C-ethyleneoxy-bridged 2'-deoxyribonucleic acids with exocyclic methylene groups.Therapeutic oligonucleotides with polyethylene glycol modifications.Guanidine bridged nucleic acid (GuNA): an effect of a cationic bridged nucleic acid on DNA binding affinity.Quantum mechanical studies of DNA and LNA.Concise postsynthetic preparation of oligonucleotide-oligopeptide conjugates through facile disulfide bond formation.Application of modified antisense oligonucleotides and siRNAs as antiviral drugs.Biological applications of xeno nucleic acids.The chemical evolution of oligonucleotide therapies of clinical utility.Solid-Phase Synthesis of Oligodeoxynucleotide Analogs Containing Phosphorodithioate Linkages.Jumonji/Arid1b (Jarid1b) protein modulates human esophageal cancer cell growth.The chemistry and biology of oligonucleotide conjugates.Desulfurization of phosphorothioate oligonucleotides via the sulfur-by-oxygen replacement induced by the hydroxyl radical during negative electrospray ionization mass spectrometry.Versatile Method for the Site-Specific Modification of DNA with Boron Clusters: Anti-Epidermal Growth Factor Receptor (EGFR) Antisense Oligonucleotide Case.Synthesis and properties of 2'-O,4'-C-spirocyclopropylene bridged nucleic acid (scpBNA), an analogue of 2',4'-BNA/LNA bearing a cyclopropane ring.Cellular Antisense Activity of PNA-Oligo(bicycloguanidinium) Conjugates Forming Self-Assembled Nanoaggregates.Hydrogen peroxide-triggered gene silencing in mammalian cells through boronated antisense oligonucleotides.Oligonucleotides containing a piperazino-modified 2′-amino-LNA monomer exhibit very high duplex stability and remarkable nuclease resistance
P2860
Q31106565-B352CBDE-885C-4F36-95B6-CE4D8DCF2F83Q33843195-DD4FB281-A695-4CC7-B8EE-0F19E7414818Q33931423-AEDACF1F-BBDF-4864-8C6E-D44F43CEDDDAQ36009522-7195C40B-746D-452A-91AB-2604B7E4C4B5Q36016288-BDD29BD8-FF8D-474B-833B-9977072E85DCQ36086300-BB877CD8-670E-4AA6-A1A4-74FBFCD266C8Q36228008-CE73E71D-2A7F-41E5-8B75-E280FEC01BDCQ36296557-CEBCE9C4-EE94-4221-9D2F-99366B710D8EQ36740806-7A76C1A8-F133-4E16-96D0-52C1832BB580Q37387192-56E201FA-1CD4-4951-9674-A3B83C85923AQ37933197-CF94F3E1-DBEA-44B8-9557-5F9C9E9C7204Q38085679-85785480-D24B-4045-8D1F-988C049738DAQ38123854-EB634D25-5A90-48BF-BBD1-2942E297E4D1Q38138569-3B2BC9CD-3C72-451C-BC01-03F89D5D3977Q38195295-30EDA221-4825-47BB-A138-FF53D7292141Q38288070-9590243C-D68A-49B4-9AE7-70B20C31DF01Q38290684-EDA9D20D-B531-4F2B-A02F-FDF72F46E1E7Q38296021-5C56A56B-0FFB-469C-B7B4-3C0840B1D675Q38310952-B437A5C6-D734-487D-9073-B70BCA7851F7Q38405255-C944C5DA-2374-4F26-9924-72CC158924CFQ38834667-59F4264A-B45E-4538-80A5-A74D9AF6546CQ38962711-C8205D7C-A06A-41FA-BA66-55C24785D55AQ39003630-EF4B1EB0-7F11-43F1-8CDC-2A7A96470AF7Q39154511-75962040-1DF6-47F3-B4AA-F40BBD1D8670Q40598448-1E69A666-546A-4E79-A35D-2ACBEE11CE29Q41920696-6C120B8F-541D-4499-ADD1-523EC43CAB18Q42011018-C99FE595-0DDD-4C0D-B862-AAF87B31510BQ44365925-90697E04-104B-48C2-ADCF-08888A47F037Q47651762-B29F49ED-D8DF-4698-A12A-E35A2BF5499DQ47703250-956D788B-8349-4EB3-A13F-5F8BD7DD265FQ48798795-8FDBC34C-6EF7-4871-8946-C7ACFEB29836Q52599519-13A68A12-A474-4018-9FCD-E6E92170BB34Q59003688-6CEE564E-AC5C-4F79-A4A0-717AC38D5B85
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Antisense drug discovery and development.
@en
Antisense drug discovery and development.
@nl
type
label
Antisense drug discovery and development.
@en
Antisense drug discovery and development.
@nl
prefLabel
Antisense drug discovery and development.
@en
Antisense drug discovery and development.
@nl
P2093
P2860
P356
P1476
Antisense drug discovery and development.
@en
P2093
Keisuke Narukawa
Moeka Nakatani
Satoshi Obika
Tsuyoshi Yamamoto
P2860
P304
P356
10.4155/FMC.11.2
P577
2011-03-01T00:00:00Z